Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

	Summary Compensation Table (SCT) Total for CEO(1) ($)	Compensation Actually Paid (CAP) to CEO(1)(2) ($)	Average SCT Total for Other NEOs(1) ($)	Average CAP to Other NEOs(1)(2) ($)	Value of Initial Fixed $100 Investment Based On:		Net Income ($ in millions)	Revenue (Company Selected Measure) ($ in millions)
Year					Zoetis TSR ($)	S&P 500 Pharmaceuticals Index TSR ($)
2024	17,206,760	759,623	3,351,274	1,095,197	127.80	159.21	2,486	9,256
2023	15,237,853	26,369,229	2,994,932	4,592,358	153.30	147.14	2,344	8,544
2022	14,003,540	(15,709,790)	2,931,816	(3,076,052)	112.80	146.65	2,114	8,080
2021	13,098,491	33,519,679	4,455,516	10,261,897	186.46	135.22	2,037	7,776
2020	10,374,312	15,564,796	3,756,846	6,519,899	125.76	107.52	1,638	6,675

Company Selected Measure Name

Revenue

Named Executive Officers, Footnote

In all years shown Kristin C. Peck was our Chief Executive Officer. The other named executive officers (NEO) represent the following individuals: for 2024, Wetteny Joseph, Robert J. Polzer, Jamie Brannan, Roxanne Lagano, Heidi C. Chen, and Wafaa Mamilli; for 2023, Wetteny Joseph, Heidi C. Chen, Wafaa Mamilli and Robert J. Polzer; for 2022, Wetteny Joseph, Glenn C. David, Heidi C. Chen, and Wafaa Mamilli; for 2021, Wetteny Joseph, Glenn C. David, Catherine A. Knupp, Roman Trawicki and Heidi C. Chen; and for 2020, Glenn C. David, Catherine A. Knupp, Roman Trawicki and Wafaa Mamilli.

PEO Total Compensation Amount

$ 17,206,760

$ 15,237,853

$ 14,003,540

$ 13,098,491

$ 10,374,312

PEO Actually Paid Compensation Amount

$ 759,623

26,369,229

(15,709,790)

33,519,679

15,564,796

Adjustment To PEO Compensation, Footnote

To calculate Compensation Actually Paid (CAP) the following amounts were deducted from and added to the Summary Compensation Table (SCT) total compensation:

CEO SCT Total to CAP Reconciliation:

		Deductions from SCT Total(a)
Year	SCT Total ($)	Stock Awards ($)	Options Awards ($)	Additions to SCT Total(b) ($)	Compensation Actually Paid ($)
2024	17,206,760	(9,562,347)	(3,187,500)	(3,697,290)	759,623
2023	15,237,853	(8,774,860)	(2,924,967)	22,831,203	26,369,229
2022	14,003,540	(8,399,841)	(2,799,966)	(18,513,523)	(15,709,790)
2021	13,098,491	(6,929,797)	(2,309,970)	29,660,955	33,519,679
2020	10,374,312	(5,684,840)	(1,894,975)	12,770,299	15,564,796

CEO Equity Component of CAP:

Year	Equity Type	Fair Value of Current Year Equity Awards at End of Year ($)	Change in Value of Prior Years’ Awards Unvested at End of Year ($)	Change in Value of Prior Years’ Awards That Vested During the Year ($)	Equity Value Included in CAP ($)
2024	Stock Options	1,599,375	(2,205,096)	(40,922)	(646,643)
	Restricted Stock Units	2,668,416	(867,090)	5,906	1,807,232
	Performance Award Units	2,859,270	(7,726,027)	8,878	(4,857,879)
	Total	7,127,061	(10,798,213)	(26,138)	(3,697,290)
2023	Stock Options	3,971,133	1,923,431	372,068	6,266,632
	Restricted Stock Units	3,585,639	1,500,387	162,461	5,248,488
	Performance Award Units	8,054,738	3,060,551	200,795	11,316,083
	Total	15,611,510	6,484,369	735,324	22,831,203
2022	Stock Options	1,528,648	(7,897,241)	(931,398)	(7,299,991)
	Restricted Stock Units	2,049,978	(2,672,369)	(234,149)	(856,541)
	Performance Award Units	2,460,116	(12,009,652)	(807,455)	(10,356,991)
	Total	6,038,742	(22,579,262)	(1,973,002)	(18,513,523)
2021	Stock Options	5,709,571	5,052,274	33,020	10,794,866
	Restricted Stock Units	3,523,058	1,469,682	10,165	5,002,905
	Performance Award Units	8,916,215	4,932,126	14,842	13,863,183
	Total	18,148,844	11,454,083	58,027	29,660,955
2020	Stock Options	2,309,500	1,341,931	385,408	4,036,839
	Restricted Stock Units	2,186,374	411,103	103,798	2,701,275
	Performance Award Units	4,749,437	1,128,981	153,769	6,032,186
	Total	9,245,311	2,882,015	642,974	12,770,299

Non-PEO NEO Average Total Compensation Amount

$ 3,351,274

2,994,932

2,931,816

4,455,516

3,756,846

Non-PEO NEO Average Compensation Actually Paid Amount

$ 1,095,197

4,592,358

(3,076,052)

10,261,897

6,519,899

Adjustment to Non-PEO NEO Compensation Footnote

Average Other NEOs SCT Total to CAP Reconciliation:

		Deductions from SCT Total(a)
Year	SCT Total ($)	Stock Awards ($)	Options Awards ($)	Additions to SCT Total(b) ($)	Compensation Actually Paid ($)
2024	3,351,274	(1,236,913)	(412,369)	(606,795)	1,095,197
2023	2,994,932	(1,239,133)	(413,112)	3,249,671	4,592,358
2022	2,931,816	(1,405,542)	(468,570)	(4,133,756)	(3,076,052)
2021	4,455,516	(2,118,241)	(366,105)	8,290,727	10,261,897
2020	3,756,846	(1,302,977)	(496,860)	4,562,890	6,519,899

(a)These deductions are the amounts listed in the “Stock Awards” and “Option Awards” columns of the SCT and represent the grant date fair value of equity-based awards granted each year.

(b)Reflects the value of equity calculated in accordance with the SEC methodology for determining CAP for each year shown. The equity component for each year is detailed in the supplemental table below:

Average Other NEOs Equity Component of CAP:

Year	Equity Type	Fair Value of Current Year Equity Awards at End of Year ($)	Change in Value of Prior Years’ Awards Unvested at End of Year ($)	Change in Value of Prior Years’ Awards That Vested During the Year ($)	Equity Value Included in CAP ($)
2024	Stock Options	177,330	(251,572)	(2,688)	(76,930)
	Restricted Stock Units	303,934	(131,626)	(106,952)	65,356
	Performance Awards Units	324,800	(920,604)	583	(595,221)
	Total	806,064	(1,303,802)	(109,057)	(606,795)
2023	Stock Options	560,869	169,611	46,139	776,619
	Restricted Stock Units	506,345	509,551	20,141	1,036,037
	Performance Award Units	1,137,439	284,615	14,962	1,437,015
	Total	2,204,652	963,777	81,242	3,249,671
2022	Stock Options	255,817	(1,352,757)	(446,281)	(1,543,221)
	Restricted Stock Units	343,039	(1,110,941)	(112,191)	(880,093)
	Performance Award Units	411,640	(1,735,180)	(386,902)	(1,710,442)
	Total	1,010,496	(4,198,878)	(945,373)	(4,133,756)
2021	Stock Options	904,905	1,796,558	22,234	2,723,696
	Restricted Stock Units	1,897,216	490,667	6,844	2,394,727
	Performance Award Units	1,413,054	1,749,257	9,993	3,172,304
	Total	4,215,175	4,036,482	39,071	8,290,727
2020	Stock Options	605,548	908,841	240,880	1,755,269
	Restricted Stock Units	573,225	278,702	64,872	916,799
	Performance Award Units	1,010,271	784,446	96,105	1,890,822
	Total	2,189,044	1,971,988	401,857	4,562,890

Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid (CAP) versus Zoetis TSR

The graph below compares the Compensation Actually Paid (CAP) of the CEO and the Other NEOs, to Zoetis’ TSR for the five fiscal years beginning with 2020. As the graph shows, the CAP to the CEO and Other NEOs is directionally aligned with the Company’s TSR.

CAP vs. TSR: Zoetis

n CEO Cap n Other NEO Avg. CAP   Zoetis TSR

Compensation Actually Paid vs. Net Income

CAP versus Net Income

The graph below compares the CAP of the CEO and the Other NEOs, to Zoetis’ net income for the five fiscal years beginning with 2020. Net Income has steadily increased while the CEO and Other NEOs CAP has varied by year. Zoetis does not use net income as a metric in its compensation incentives.

CAP vs. Net Income

($ in millions)

n CEO Cap n Other NEO Avg. CAP   Net Income

Compensation Actually Paid vs. Company Selected Measure

CAP versus Revenue (Company Selected Measure)

The graph below compares the CAP of the CEO and the Other NEOs, to Zoetis’ revenue for the five fiscal years beginning with 2020. Revenue has steadily increased while the CEO and Other NEOs’ CAP has varied by year. While revenue is a metric in Zoetis’ AIP, the weight of equity-based LTI — which primarily reflect stock price and relative TSR — exceeds the weight of our annual incentive in the total compensation for executives.

CAP vs. Revenue (CSM)

($ in millions)

n CEO Cap n Other NEO Avg. CAP   Revenue

Total Shareholder Return Vs Peer Group

Total Shareholder Return (TSR): Zoetis versus S&P 500 Pharmaceuticals Index

The graph below compares an initial investment in our common stock of $100 on December 31, 2019, versus the same investment in the S&P 500 Pharmaceuticals Index (assuming dividends, if any, were reinvested). It should be noted that the companies in the S&P 500 Pharmaceuticals index are not the same as those used for our compensation benchmarking, nor are they the same as the S&P 500, which is the group of companies we use to determine Relative TSR for the company’s performance award unit metric, as described in the CD&A.

TSR: Zoetis vs. S&P 500 Pharmaceuticals Index

  Zoetis TSR   S&P 500 Pharmaceuticals TSR

Tabular List, Table

Most Important Performance Measures

Relative Total Shareholder Return(a)

Revenue(b)

Adjusted Diluted EPS(b)

Free Cash Flow(b)

Total Shareholder Return Amount

$ 127.80

153.30

112.80

186.46

125.76

Peer Group Total Shareholder Return Amount

159.21

147.14

146.65

135.22

107.52

Net Income (Loss)

$ 2,486,000,000

$ 2,344,000,000

$ 2,114,000,000

$ 2,037,000,000

$ 1,638,000,000

Company Selected Measure Amount

9,256,000,000

8,544,000,000

8,080,000,000

7,776,000,000

6,675,000,000

PEO Name

Kristin C. Peck

Additional 402(v) Disclosure

The four items listed below represent the most important metrics we used to determine CAP for 2024 as further described in our CD&A within the sections titled “Annual Incentive Plan” and “Long-Term Incentives”:

Relative Total Shareholder Return is the 3-year performance metric used for Zoetis’ performance award units, which comprise 50% of the long-term incentive compensation of our NEOs, including the CEO. Total Shareholder Return (TSR) is the appreciation of share price, including dividends, during the performance period. Relative TSR is Zoetis’ TSR as compared to the TSR over the performance period of the “S&P 500 Group”, which we define as the companies comprising the S&P 500 stock market index as of the beginning of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded.

(b)Revenue, Adjusted Diluted EPS and Free Cash Flow refer to the measures used to assess performance in determining the funding for our Annual Incentive Plan (AIP) and exclude the impacts of foreign exchange and certain other adjustments as described in the CD&A.

Measure:: 1

Pay vs Performance Disclosure

Name

Relative Total Shareholder Return

Measure:: 2

Pay vs Performance Disclosure

Name

Revenue

Measure:: 3

Pay vs Performance Disclosure

Name

Adjusted Diluted EPS

Measure:: 4

Pay vs Performance Disclosure

Name

Free Cash Flow

PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ (3,697,290)

$ 22,831,203

$ (18,513,523)

$ 29,660,955

$ 12,770,299

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

7,127,061

15,611,510

6,038,742

18,148,844

9,245,311

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(10,798,213)

6,484,369

(22,579,262)

11,454,083

2,882,015

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(26,138)

735,324

(1,973,002)

58,027

642,974

PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member]

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(9,562,347)

(8,774,860)

(8,399,841)

(6,929,797)

(5,684,840)

PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member]

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(3,187,500)

(2,924,967)

(2,799,966)

(2,309,970)

(1,894,975)

PEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

1,599,375

3,971,133

1,528,648

5,709,571

2,309,500

PEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(2,205,096)

1,923,431

(7,897,241)

5,052,274

1,341,931

PEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(40,922)

372,068

(931,398)

33,020

385,408

PEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(646,643)

6,266,632

(7,299,991)

10,794,866

4,036,839

PEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

2,668,416

3,585,639

2,049,978

3,523,058

2,186,374

PEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(867,090)

1,500,387

(2,672,369)

1,469,682

411,103

PEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

5,906

162,461

(234,149)

10,165

103,798

PEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

1,807,232

5,248,488

(856,541)

5,002,905

2,701,275

PEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

2,859,270

8,054,738

2,460,116

8,916,215

4,749,437

PEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(7,726,027)

3,060,551

(12,009,652)

4,932,126

1,128,981

PEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

8,878

200,795

(807,455)

14,842

153,769

PEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(4,857,879)

11,316,083

(10,356,991)

13,863,183

6,032,186

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(606,795)

3,249,671

(4,133,756)

8,290,727

4,562,890

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

806,064

2,204,652

1,010,496

4,215,175

2,189,044

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,303,802)

963,777

(4,198,878)

4,036,482

1,971,988

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(109,057)

81,242

(945,373)

39,071

401,857

Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member]

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,236,913)

(1,239,133)

(1,405,542)

(2,118,241)

(1,302,977)

Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member]

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(412,369)

(413,112)

(468,570)

(366,105)

(496,860)

Non-PEO NEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

177,330

560,869

255,817

904,905

605,548

Non-PEO NEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(251,572)

169,611

(1,352,757)

1,796,558

908,841

Non-PEO NEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(2,688)

46,139

(446,281)

22,234

240,880

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Stock Options [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(76,930)

776,619

(1,543,221)

2,723,696

1,755,269

Non-PEO NEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

303,934

506,345

343,039

1,897,216

573,225

Non-PEO NEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(131,626)

509,551

(1,110,941)

490,667

278,702

Non-PEO NEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(106,952)

20,141

(112,191)

6,844

64,872

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Restricted Stock Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

65,356

1,036,037

(880,093)

2,394,727

916,799

Non-PEO NEO | Year-End Fair Value Of Equity Awards Granted In Covered Year That Are Outstanding And Unvested, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

324,800

1,137,439

411,640

1,413,054

1,010,271

Non-PEO NEO | Year-Over-Year Change In Fair Value Of Equity Awards Granted In Prior Years That Are Outstanding And Unvested, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

(920,604)

284,615

(1,735,180)

1,749,257

784,446

Non-PEO NEO | Change In Fair Value As Of Vesting Date Of Prior Year Equity Awards Vested In Covered Year, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

583

14,962

(386,902)

9,993

96,105

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported In The Compensation Table, Performance Award Units [Member]

Pay vs Performance Disclosure

Adjustment To Compensation Amount, Equity Awards

$ (595,221)

$ 1,437,015

$ (1,710,442)

$ 3,172,304

$ 1,890,822